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Abstract
Background: Illicit use of  high dosage buprenorphine has been well documented in several countries, including Tunisia. 
Objectives: The aim of  this survey is to assess the buprenorphine withdrawal syndrome time course, and how it may be affected 
by the population characteristics among subjects admitted to a rehabilitation center in Tunisia.
Methods: A prospective research has permitted study of  the socio-demographic characteristics and assessment of  buprenor-
phine withdrawal syndrome among 32 subjects admitted for buprenorphine dependence by using the clinical opiate withdrawal 
scale. An ANOVA was conducted to examine the effect of  different factors on the withdrawal scores.
Results: 32 subjects were included. Among them 30 were males, 27 had been injecting buprenorphine, 16 were poly-drug 
abusers and 2 had a history of  mental disorders. Buprenorphine withdrawal syndrome was of  a mild intensity and had a de-
layed onset. Withdrawal mean scores varied between 0 and 9, and maximum values were reached at day 21. These scores varied 
significantly over time (p<0,001). The sex v time interaction and the mode of  consumption of  buprenorphine had significant 
effects on the withdrawal scores (p<0,001). The poly-drug consumption and the history of  mental disorders did not have any 
significant effect on the withdrawal scores.
Conclusion: This study has permitted description of  buprenorphine withdrawal syndrome among patients going through a 
detoxification treatment at a rehabilitation center. Understanding this syndrome would help elaborate effective and suitable bu-
prenorphine dependence management plans. 
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Introduction
Buprenorphine is a semi-synthetic opioid derived from 
thebaine, discovered in the early 1970s1. It was firstly mar-
keted for parenteral use at low doses of0.3mg/mL in 1978 
in the United-Kingdom, under the name Temgésic®. At 
that time it was used as an analgesic for post-operative 
and cancer patients. Ever since, buprenorphine has gen-
erated a lot of  interest in the treatment of  opioid depen-
dence and its effectiveness for this has been proven at 
high doses2. Later,in 1995, France was the first country to 
market high-dosage buprenorphine (HDB), as Subutex®, 
for opioid maintenance therapy. Subutex was available in 
sublingual tablets formulated at 0.4 mg, 2.0 mg and 8.0 
mg doses. 
Though buprenorphine has provided a major advance in 
opioid dependence treatment, as it is so widespread, cases 
of  abuse and diversion have been widely documented . 
In the Middle East and North Africa (MENA), opioid 
substitution treatment is only available in 5 out of  the 20 
countries, yet, HDB is one of  the most abused drugs by 
People Who Inject Drugs (PWID) in the region5.
In Tunisia, Subutex® does not have a license to be mar-
keted and, hence, is not used in medical practice. Howev-
er, it is smuggled across borders and is widely trafficked 
for misuse. According to some Non-Governmental Or-
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ganizations (NGO) reports, the estimated number of  
PWID was around 9000 in 20115, and HBD was the most 
abused drug. Even though these numbers are growing 
from year to year, there are no legal specifications relat-
ed to substance abuse treatments or opioid substitution 
therapies. The only residential rehabilitation program 
available in the country has been provided in a center run 
by the Tunisian Association for the Prevention of  Drug 
Use “ATUPRET”6. 
In 2013, half  of  the center’s admissions were related to 
HDB diversion and abuse7. For buprenorphine abusers, 
ATUPRET center offers medical care services through-
out the spontaneous drug withdrawal process. This is 
why the understanding of  the buprenorphine withdrawal 
syndrome is needed for a proper medical management. 
Previous studies that have described this syndrome were 
either laboratory-based, conducted on small samples, or 
included subjects that were not necessarily buprenor-
phine dependent .
This study was conducted in order to assess the opiate 
withdrawal syndrome in buprenorphine dependent pa-
tients. The syndrome’s time course evolution was de-
scribed and analyzed in accordance with the population 
characteristics.
Methods
Study context and sample
The present study followed buprenorphine withdraw-
al syndrome in subjects who sought treatment for bu-
prenorphine dependence from the ATUPRET rehabilita-
tion center between February and May 2015. The center 
has only provided its services to male subjects. However, 
as a form of  a trial led in April 2015, it allowed 10 female 
patients suffering from different types of  dependence to 
be admitted. 
Subjects recruited for this study were those who had 
completed three out of  the four-week treatment proto-
col specified by the center. Thirty males and two female 




Socio-demographic data was collected using a form 
that was conceived after analyzing the medical and the 
social records of  other patients admitted to the center. 
The form included items pertaining to each patient’s de-
mographics, medical history, other substance abuse and 
addictive behavior. Permission was given to visit the re-
habilitation center twice a week and ethical approval was 
obtained from the center’s board. 
Withdrawal score
The buprenorphine withdrawal syndrome was assessed 
using the Clinical Opiate Withdrawal Scale (COWS). It 
consists of  11 observed (clinician-rated) and subjective 
(patient-rated) items. The score attributed to each item 
reflects the severity of  the symptom. The following cut- 
scores for the COWS have been offered: 5-12= mild, 13-
24= moderate, 25-36 moderately severe, and >36 severe 
withdrawal11.
Measures
COWS score was measured twice a week, during the pa-
tient’s stay in the center. The measures were named V1, 
V2, V3, V4, V5, V6, V7 and V8 corresponding respec-
tively to days  3,7,10,14,17,21,24 and 28 of  the patient’s 
stay. The score was then calculated according to the ob-
served withdrawal signs as well as those reported by the 
patient during the interview. 
All the data was collected anonymously and after the sub-
ject’s consent.
Data analysis
The data was collected and analyzed using IBM SPSS and 
Microsoft Excel 2013. Descriptive statistics were pro-
duced according to the demographic characteristics and 
withdrawal scores. 
Peak scores on the COWS were determined for each 
measure, and data was analyzed using repeated-measures 
one factor Analysis of  Variance (ANOVA). Time course 
differences according to the population characteristics 
(gender, means of  buprenorphine intake, history of  men-
tal disorder and nature of  the addiction) were examined 
using repeated measures mixed model ANOVA (charac-
teristic, time and characteristic × time). The degrees of  
freedom were adjusted using Greenhouse-Geisser cor-
rections for violation of  the sphericity assumption.  Pair-
wise comparisons for significant main effects were exam-
ined using Bonferroni adjustment. Statistical significance 
was indicated when p-value < 0.05.
Results
Population characteristics
A total of  32 individuals were included, 30 were male and 
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2 female. The mean age was 38.3± 9.8 years (Table 1). 
They were mostly unmarried (n=21), only 17 were em-
ployed, and 14 reported elementary school or lower level 
of  education. Infection with the Hepatitis C virus was 
found in 53.1% of  the patients, 3.1% were HBV positive 
and 18.6% were HIV positive. The presence of  mental 
disorders was reported by 2 subjects, without any speci-
fications regarding the disorder itself.  All subjects were 
smokers and 16 were abusing different substances other 
than buprenorphine (Table 1).
Buprenorphine abuse pattern
The majority (n=27) reported intravenous intake and the 
daily intake varied from 1 to 10 mg, the mean dose was 
6.22mg (SD=3.6). The mean duration of  buprenorphine 
abuse was 11.7 years (SD =7.79).
Withdrawal scores
Withdrawal scores on the COWS varied between 0 and 
9. The mean score increased progressively from an initial 
value of  3.40 (SD= 1.58) on V1 to reach a maximum val-
ue of  6.1 (SD=1.47) on V5 then decreased during the last 
week, to a value of  1.97 (SD=.92) by V8.  Before V4, all 
scores were <5 (Figure1).
On repeated measure ANOVA a significant effect of  
time was observed (F=51.2, p<0,001). Significant differ-
ences on Bonferroni comparisons of  COWS ratings were 
found on V4 and V7 (scores on V4 being higher).
Withdrawal scores varied differently upon the popula-
tion’s characteristics. The Table 2 summarizes statistical 
results from the repeated measures mixed model ANO-
VA for the different effects of  characteristics and interac-
tions on COWS ratings. 
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Table 1 : sociodemographic characteristics 
 Subjects Missing (%) 
Sex (males), n(%) 30 (93.8%) 0 
Mean Age (SD) 38.34 (9.81) 0 
Nationality (Tunisian), n (%) 20 (68.8) 0 
Marital status (married), n (%) 11(34.4) 0 
Homeless, n(%) 2 (6.3) 0 
Serology (known), n(%) 24 (75) 25 
Hepatitis C (positive), n(%) 17 (53.1) 0 
Hepatitis B (positive), n(%) 1 (3.1) 0 
HIV (positive), n(%) 6 (18.6) 0 
Education (elementary school or less), n(%) 14 (51.9) 15.6 
Employed, n(%) 17(53.1) 3.1 
History of mental disorders, n(%) 2 (6.25)  
Poly-drug abuser, n(%) 16 (53.3) 6.3 
Cannabis 11 (36.7) 0 
Alcohol 16 (53.3) 0 
Lorazepam 5 (15.6) 0 
Tobacco 32 (100) 0 
IV user, n(%) 27(84.4) 0 
   
 HIV : Human Immunodeficiency Virus 
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Effect of  the gender on withdrawal ratings
The ANOVA revealed a significant effect of  the interac-
tion gender × time on the withdrawal scores. Thus, scores 
on the COWS depended upon gender and time. The anal-
ysis of  the main simple effects revealed a significant ef-
fect of  time on withdrawal scores for both men (F=65.4, 
p<0.001) and women (F=10.8, p<0.001). A significant 
effect of  gender on withdrawal scores was been found 
on V1 (F=6.8, p=0.014) and V2 (F=6.8, p=0.007) and 
the scores were higher for the female patients. For the 
rest of  the withdrawal period, no significant difference 
was found.
Bonferroni multiple comparisons were used to compare 
the withdrawal time course for each gender. For women, 
the initial score on V1 (M=6 ±0.0) was only significantly 
different than the score measured on V8 (M=1.5±0.707) 
p=0.014. However, men’s scores increased significantly 
from V1 (M=3.23±1.48) to V3 (M=4.27±1.31, p=0.006) 
and V4 (M=5.57±1.59, p=0.001) then decreased sig-
nificantly on V7(M=3.32±1.21, p<0.001) and V8 
(M1.99±0.91, p<0.001).
Therefore, withdrawal was significantly more intense for 
woman during the first week (V1 and V2). For each gen-
der, scores did not vary in the same way as withdrawal rat-
ings for men varied more frequently during the treatment 
period (Figure1).
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Table 1 : Statistical summary of the ANOVA analysis 
Measure F p-value 
gender×time F (4.24 , 127.3) = 2.89  0.023 
Means of intake×time F (4.11 , 123.3) = 0.565 0.693 
History of psychaitric 
disorder×time 
F (4.26 , 110.9) = 11.02 0.348 
Nature of dependance×time F (3.97 , 111.1) = 0.58 0.676 
 
 
Interactions for which p<0.05 are considered significant 
Table 2: Statistical summary of the ANOVA analysis 
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Effect of  the means of  intake on withdrawal ratings
The analysis of  data did not find a significant effect of  
the interaction means of  intake × time on COWS rat-
ings (F=0.565, p=0,693). However, it revealed significant 
main effects of  the means of  intake (F=7.47, p=0.01) 
and time (F=22.41, p<0.001) on the withdrawal scores.
Figure 1: Evolution of  withdrawal scores by patient’s gender; Women withdrawal scores, measured using the COWS 
were, overall, higher than men scores . The intersection between the two plots indicates a significant effect of  the 
interaction gender×time\r\n
Withdrawal scores measured for the individuals who 
were injecting buprenorphine (M=4, 45±0,155) were sig-
nificantly higher compared to those who were snorting 
the drug (M=3.38±0.36). The figure 2 shows that, even 
though the injector group had higher COWS scores, the 
withdrawal plots of  the two groups varied in the same 
way without any intersections.
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Figure 2: Evolution of  withdrawal scores by the route of  buprenorphine abuse
Effect of  the history of  the mental disorders on with-
drawal ratings
The population was divided into two groups according 
to the history of  mental disorders. The effect of  the in-
teraction of  the history of  mental disorders × time was 
not significant, and neither was the effect of  the history 
of  mental disorders alone. Only time was found to have 
a significant effect (F=11.02, p<0,001) on the withdrawal 
scores within the two groups. (Figure3)
Figure 3: Evolution of  withdrawal scores according to patients’ psychiatric history; Withdrawal scores were measured 
using The COWS for patients with a history of  a mental disorder    and those who had not reported any. No signifi-
cant difference was found between the two groups; 
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Withdrawal management
Withdrawal management in the center was mainly symp-
tomatic. Medications used were from the therapeutic 
classes: non-opioid analgesics, non-steroidal anti-inflam-
matory drugs, antispasmodics, antihistamines and benzo-
diazepines.
Discussion
The main findings of  this study allowed assessment of  
the evolution and the characteristics of  the opioid with-
drawal syndrome in subjects with buprenorphine depen-
dence without a maintenance treatment using the COWS.
Most of  these demographic characteristics of  the 32 indi-
viduals included are consistent with findings from previ-
ous studies describing the Tunisian buprenorphine abus-
er profile7,12. Subjects were mainly men, unmarried and 
almost half  of  them were unemployed. Celibacy, unem-
ployment and low levels of  education have also been as-
sociated to buprenorphine abuse in other countries such 
as Canada and Finland13,14. 
Buprenorphine was abused mainly by IV route (84.4%)
which may explain the high prevalence of  Hepatitis C vi-
rus (HCV) (53.1%), Hepatitis B (3.1%) virus (HBV) and 
HIV (18.6%) infection. These results are similar to the 
results found in a study led in 2007 by Kilani B et al. 
evaluating the concomitant infection by HCV and HIV 
in Tunisia. It was found that 39.7% of  the HIV- positive 
included patients were also HCV-positive and that most 
of  them (78.4%) had a  history of  drug injection7. Thus, 
those results along with the findings of  this current study 
highlight the burden of  the rapid expansion of  HIV and 
HCV coinfection in PWID in Tunisia.
Buprenorphine withdrawal syndrome assessed in the 
population had a delayed appearance and a mild inten-
sity. In fact, according to the COWS, scores have to be 
≥5 in order to indicate the presence of  opioid withdraw-
al, while during the first two weeks of  the study, all rat-
ings were <5. A mild withdrawal was measured from V4 
(day14) to V6 (day 21). These results can be explained by 
buprenorphine’s pharmacokinetics and pharmacodynam-
ics. The compound is lipophilic. It shows a high volume 
of  distribution and distributes well in tissues including 
the brain. Buprenorphine has a long elimination half-life, 
is highly protein- bound (96%) and has a great affinity to 
µ opioid receptors2,15. In addition, buprenorphine under-
goes  glucuronidation into buprenorphine-3- glucuronide 
and it seems that this metabolite may be reabsorbed as 
buprenorphine after entero-hepatic recirculation16.  The 
combination of  these properties may have contributed 
to prolonging the effect of  buprenorphine, after the last 
intake, enough to dissimulate withdrawal signs during the 
first 14 days of  the process. The medication also slowly 
dissociates from µ receptors1.  While studying the effect 
of  buprenorphine on µ receptors on heroin dependent 
individuals, Greenwald et al stated that the appearance of  
withdrawal signs was highly correlated to the buprenor-
phine µ receptors occupancy rates. They also found that 
almost 20% of  the receptors were occupied by the mol-
ecule 76 hours after the last buprenorphine’s administra-
tion17. Therefore, buprenorphine slow rates of  dissocia-
tion from µ receptors might have allowed the return of  
cellular homeostasis in the parts of  the central nervous 
system (CNS) thought to be responsible for opioid with-
drawal  resulting, thereby, in a mild withdrawal syndrome.
Withdrawal scores measured for female patients were 
higher than those measured for males. The interaction 
gender × time was significant indicating that the time 
course of  withdrawal did not follow the same schema for 
the two genders.
Two main factors may explain the gender-related dif-
ference noted in the withdrawal ratings. The first one is 
due to the innate difference between men and women in 
the somatic and visceral perception. In order to measure 
withdrawal score, the COWS evaluates the levels of  bone 
and joint aches as well as gastro intestinal cramps11. How-
ever, males and females may label and describe the same 
noxious sensation differently. It has also been found that 
pain threshold for women was lower. On a biological lev-
el, the effect that sexual hormones have on the CNS and 
the menstrual cycle was shown to influence sensitivity to 
pain18.  Zubieta et al, have been examining µ receptors 
binding differences between men and women, they found 
that women showed more µ-opioid receptor availability 
than men in several brain regions, meaning that anti-noci-
ception and reward systems may be modulated differently 
according to the gender.  
The second reason is related to buprenorphine’s phar-
macokinetics. Moody D.E et al stated that after the ad-
ministration of  equivalent doses of  buprenorphine, the 
compound did not show the same kinetics for the two 
sexes. Females were exposed to higher levels of  bu-
prenorphine and its metabolites. In normal therapy, this 
may be non-critical19. However, it could be taken into 
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consideration when dealing with cases of  buprenorphine 
dependence and abuse. 
For now, the issues of  the gender differences in buprenor-
phine withdrawal perception are not known. Long-term 
follow-up is necessary in order to understand if  these 
facts may influence treatment outcome or be associated 
to relapses. 
Withdrawal scores for buprenorphine injectors (84.4% 
of  the population), were significantly higher compared 
to patients who were abusing it by nasal route. The effect 
of  the interaction means of  intake × time was not signif-
icant. This result was expected since µ-opioid receptors 
occupancy rates depend on buprenorphine plasma con-
centration , and thus, bioavailability which varies accord-
ing to the route of  administration. When used intrave-
nously, buprenorphine bioavailability is 100% versus 50% 
when it is snorted7. Furthermore, the amount of  drug 
wasted would be greater after nasal intake.
Two patients reported that they had suffered from a men-
tal disorder before they were admitted to the rehabilita-
tion center and the nature of  the disorder was not speci-
fied. Furthermore, the lack of  data related to psychiatric 
counseling in the medical records did not allow determi-
nation as to whether or not other cases were diagnosed 
during their stay in the center.
The relationship between psychiatric disorders and sub-
stance use disorders is complex22.
When we compared withdrawal in subjects suffering from 
psychiatric disorders with the rest of  the population, no 
significant difference between the two groups was found. 
However, these results cannot be generalized since in 
the present study the nature of  the mental disorder was 
not specified. The outcomes of  the association between 
psychiatric troubles and substance use disorder may vary 
depending on the trouble and the substance involved23,24. 
Thereby, an initial diagnosis of  psychiatric disorders be-
fore admission to the detoxification process may be man-
datory for the proper management of  withdrawal signs 
and the adequate adaptation of  the treatment, preventing 
the exacerbation of  underlying psychiatric co-morbidi-
ties23.
We found that buprenorphine abuse was associated with 
the abuse of  other psychoactive substances in 16 individ-
uals. Alcohol, cannabis, and Lorazepam were the most 
frequently abused.
The use of  cannabis and benzodiazepines is frequent 
among prescription opioids and buprenorphine users 
.Nevertheless, some of  these associations can be more 
dangerous than others and buprenorphine may become 
lethal when associated with alcohol and/ or benzodiaze-
pines. It is known that CYP3A4 inducers and inhibitors 
may reduce or improve buprenorphine N-alkylation. 
However, it appears that the interaction between bu-
prenorphine and benzodiazepines or alcohol is more like-
ly to be of  a pharmacodynamic rather than of  a pharma-
cokinetic nature26,27. The ceiling effect on the respiratory 
function of  buprenorphine may not be present when it is 
co-administered with other psychoactive drugs27. In fact, 
CNS depressants, particularly benzodiazepines, act syner-
gistically with opioids to reduce the respiratory function, 
which increases the toxicity of  opioids4,26. Therefore, 
since buprenorphine has very strong µ-receptor affinity, 
naloxone in standard doses does not reverse the effects 
of  buprenorphine and cannot be used in case of  respira-
tory depression and higher doses must be used 15,28.
Poly-drug abusers had higher withdrawal scores com-
pared to individuals abusing buprenorphine alone. This 
difference was, however, non-significant (p=0,172).
In a general manner, non-opioid drugs have little proved 
efficiency on opioid withdrawal signs and only benzodiaz-
epines have been reported to use a moderate improve on 
the withdrawal29. Nonetheless, the prolonged use exposes 
the patient to the risk of  developing a co-dependence to 
benzodiazepines30. This co-dependence may worsenthe 
opiate withdrawal. Benzodiazepine withdrawal may lead 
to a reduced GABA-ergic and an increased glutamatergic 
activity in the locus coeruleus. When this occurs concur-
rent with opiate withdrawal, it may enhance noradrena-
line release, andthereby exacerbate opiate withdrawal31. 
In this study, most patients were abusing more than two 
substances concomitantly, making it difficult to evaluate 
the effect of  each substance apart.
These results highlight the importance of  the establish-
ment of  an adapted treatment for each patient according 
to his dependence and drug abuse patterns.
The management of  the withdrawal syndrome in the 
center was symptomatic. Drugs were administered upon 
patients’ request and the clinical judgement of  nurses to 
help manage withdrawal symptoms.The most effective 
pharmacotherapies for opioid withdrawal are substitution 
therapies. The approach involves using µ-opioid agonists 
with long half-lives, such as buprenorphine and metha-
done that will reduce withdrawal symptoms and produce 
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less drug-like effects. Up to the present time, there has 
been no evidence-based guidelines for the management 
of  buprenorphine injection32. In a trial led in Iran by Ah-
madi and Ahmadi K, 204 buprenorphine injectors were 
randomized to receive methadone(orally), buprenorphine 
(sublingually) or naltrexone, an opioid antagonist, (orally) 
along with counselling sessions. By the end of  the treat-
ment period, results were in favor of  methadone33. How-
ever, these results need more investigation before they 
can be generalized32.
Some countries like the United-States2, France34 or Malay-
sia32, use Suboxone®, an association of  buprenorphine 
and naloxone, as part of  their dependence management 
plan. On terms of  effectiveness, this combination can be 
compared to Subutex® in the treatment of  opioid depen-
dence, as naloxone is not absorbed sublingually. However, 
since it can be absorbed via the IV and the nasal routes, 
Suboxone® may precipitate withdrawal and help, hence, 
reduce  buprenorphine misuse34. In 2006, the Malaysian 
government, replaced buprenorphine with the combina-
tion buprenorphine/ naloxone to address the buprenor-
phine diversion concern. After this transition, no reduc-
tion in injection related risk behaviors was stated. On the 
contrary, it was found that there was an increase in the 
consumption of  benzodiazepines and buprenorphine 
and patients have developed new methods to avoid the 
naloxone effects32. Giving the specificity of  the buprenor-
phine abuse issue, more comparative studies focusing on 
the management of  the buprenorphine withdrawal syn-
drome, should be conducted in the future to establish 
an effective treatment protocol.buprenorphine misuse34. 
In 2006, the Malaysian government, replaced buprenor-
phine with the combination buprenorphine/ naloxone to 
address the buprenorphine diversion concern. After this 
transition, no reduction in injection related risk behaviors 
was stated. Onthe contrary, it was found that there was an 
increase in the consumption of  benzodiazepines and bu-
prenorphine and patients have developed new methods 
to avoid the naloxone effects32. Giving the specificity of  
the buprenorphine abuse issue, more comparative studies 
focusing on the management of  the buprenorphine with-
drawal syndrome, should be conducted in the future to 
establish an effective treatment protocol.
In Tunisia, substitution treatments do not have a license 
to be marketed and are not legally available. This draco-
nian approach does not take into account the benefits of  
the use of  such medications on the health care system, 
especially when it comes to providing efficient treatments 
for opioid dependence. Besides, it seems that through-
out the past years, this approach was not likely to put an 
end entirely to the diversion and the misuse of  buprenor-
phine. According to a recent report of  the WHO Expert 
Committee on Drug Dependence, despite the problem-
atic increase of  the buprenorphine misuse, its risk-benefit 
balance remains favorable.
Limitations
Some limitations need to be acknowledged. Withdrawal 
assessment could not be done on a daily basis. In any 
case, the sample was divided into subgroups of  non-ho-
mogenous sizes and the subjects were not abusing the 
same amounts of  buprenorphine before getting into the 
center. Data related to daily buprenorphine intake were 
based on client’s self  reporting and, therefore, may be 
subject to recall bias.
 
Conclusion
This study has permitted the description of  the bu-
prenorphine withdrawal syndrome. Given the fact that 
the withdrawal had a mild intensity and a delayed onset, 
symptoms might be mistakenly attributed to some other 
cause by both practitioners and patients.  Adapted treat-
ment protocols should be investigated and provided to 
reduce risky behaviors. Future studies should focus on 
long-term follow-ups and evaluate the efficiency of  the 
access to opioid substitution treatment on this kind of  
dependence.
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